Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
AirSculpt Technologies (AIRS) is back in focus after reporting Q2 2026 results that showed slightly lower sales and a wider net loss, while management reaffirmed full year revenue guidance at the lower end of its range. See our latest analysis for AirSculpt Technologies. The Q2 2026 earnings release and reaffirmed revenue outlook have landed after a period of sharp share price swings for AirSculpt Technologies, with the stock up strongly year to date but total shareholder return over the past...
Despite a 2.5% revenue dip, the company posts its second consecutive quarter of case growth and expands its procedure portfolio to capture the GLP-1 market.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.